Pediatric Drugs

, Volume 4, Issue 10, pp 687–694

Lamivudine

In Children and Adolescents with Chronic Hepatitis B Virus Infection
Adis New Indication Profile

DOI: 10.2165/00128072-200204100-00005

Cite this article as:
Keam, S.J. & Scott, L.J. Pediatr-Drugs (2002) 4: 687. doi:10.2165/00128072-200204100-00005
  • 20 Downloads

Abstract

▲ Lamivudine, the negative enantiomer of 2′-deoxy-3′-thiacytidine, is a dideoxynucleoside analog that prevents hepatitis B virus (HBV) DNA synthesis by competitively inhibiting the viral reverse transcriptase and DNA polymerase stages of HBV replication and by terminating proviral DNA chain extension.

▲ A dose-ranging study established that once daily oral lamivudine 3 mg/kg up to a maximum of 100 mg/day has the optimum efficacy and tolerability profile for achieving a maximal reduction in serum HBV DNA levels in children aged 2 to 12 years and adolescents aged 13 to 17 years with chronic HBV infection and active viral replication (chronic hepatitis B).

▲ Significantly more children and adolescents with chronic hepatitis B receiving lamivudine demonstrated a virologic response (undetectable serum hepatitis Be antigen and undetectable HBV DNA level) [23 vs 13%; p=0.04] and/or biochemical response (55 vs 12%; p < 0.001) compared with placebo in a large, randomized, doubleblind, 52-week phase III study. Despite the emergence of YMDD-variant HBV in 19% of lamivudine-treated children and adolescents, serum alanine aminotransferase and HBV DNA levels remained below baseline in these patients.

▲ Oral lamivudine is generally well tolerated by children and adolescents with chronic hepatitis B, with a similar tolerability profile to placebo at the recommended once daily dosage of 3 mg/kg up to a maximum of 100 mg/day.

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Adis International Inc.LanghorneUSA

Personalised recommendations